A 90% sensitivity for Colorectal Cancer and 40% for High Risk Adenoma (HRA) in Average-Risk Adults is still insufficient! Colorectal cancer is the second-leading cause of cancer-related deaths in the U.S.A Today, one in three adults have not completed the recommended CRC screening even though colorectal cancer is curable if caught early. Our multi-omics test which adds our powerful and proprietary customeBiome platform will be a revolutionary milestone and change the CRC health outcome.

​

Pancreatic ductal adenocarcinoma accounts for more than 90% of all pancreatic cancers and its incidence has increased significantly worldwide. Patients with pancreatic ductal adenocarcinoma have a poor outcome and more than 95% of the people affected die from the disease within 12 mo after diagnosis. Surgery is the first-line treatment in the case of resectable neoplasm, but only 20% of patients are candidates for this approach. Early diagnosis is of crucial importance to improve patient outcome; therefore, we are developing the first ever screening test for Pancreatic ductal adenocarcinoma.

Immunotherapy (IO) is the use of medicines to help a person’s own immune system to recognize and destroy cancer cells.  The immune system uses “checkpoint” proteins on immune cells, which act like switches that turn on/off the immune response. Drugs that target these checkpoints are called checkpoint inhibitors.  In addition to checkpoint  genes like PD-L1 gene expression, optimizing IO is critical as starting on IO and switching to a targeted therapy can lead to adverse events. Our customeBiome atlas enables actionable IO personalized medicine in NSCLC.